B-cell Acute Lymphoblastic Leukemia Clinical Trial
Official title:
To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
The study is a non-interventional, observational, multicenter, post-marketing real-world study, and its objective is to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in the treatment of Relapsed or Refractory acute lymphoblastic leukemia. The study consists of screening period including leukapheresis, treatment period, and follow-up period (2 years at most). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03671460 -
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
|
Phase 1 | |
| Recruiting |
NCT06056752 -
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
| Suspended |
NCT01974479 -
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Completed |
NCT00289562 -
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06034275 -
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04191941 -
Treatment of Hematological Malignancy With Novel CAR-T Cells.
|
Early Phase 1 | |
| Recruiting |
NCT05333302 -
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04129099 -
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
|
Early Phase 1 | |
| Recruiting |
NCT05651191 -
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
|
Early Phase 1 | |
| Recruiting |
NCT04150497 -
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
|
Phase 1 | |
| Withdrawn |
NCT05571540 -
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03281551 -
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05379647 -
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
|
Phase 1 | |
| Withdrawn |
NCT04156659 -
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
|
Phase 2 | |
| Recruiting |
NCT04094311 -
Study of Out of Specification for Tisagenlecleucel
|
Phase 3 | |
| Completed |
NCT01207388 -
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Active, not recruiting |
NCT03467256 -
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
|
Phase 1/Phase 2 | |
| Terminated |
NCT04844086 -
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 |